Red Blood Cells: A Newly Described Partner in Central Retinal Vein Occlusion Pathophysiology?

Central retinal vein occlusion (CRVO) is a frequent retinal disorder inducing blindness due to the occlusion of the central vein of the retina. The primary cause of the occlusion remains to be identified leading to the lack of treatment. To date, current treatments mainly target the complications of the disease and do not target the primary dysfunctions. CRVO pathophysiology seems to be a multifactorial disorder; several studies did attempt to decipher the cellular and molecular mechanisms underlying the vessel obstruction, but no consensual mechanism has been found. The aim of the current review is to give an overview of CRVO pathophysiology and more precisely the role of the erythroid lineage. The review presents emerging data on red blood cell (RBC) functions besides their role as an oxygen transporter and how disturbance of RBC function could impact the whole vascular system. We also aim to gather new evidence of RBC involvement in CRVO occurrence.

[1]  W. Ageno,et al.  Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET). , 2022, Blood transfusion = Trasfusione del sangue.

[2]  A. Arrigo,et al.  Retinal vein occlusion: drug targets and therapeutic implications , 2021, Expert opinion on therapeutic targets.

[3]  M. Rozalski,et al.  Platelet and Thrombophilia-Related Risk Factors of Retinal Vein Occlusion , 2021, Journal of clinical medicine.

[4]  S. Basili,et al.  Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta‐analysis , 2020, Journal of thrombosis and haemostasis : JTH.

[5]  B. Hivert,et al.  Effects of sphingolipids overload on red blood cell properties in Gaucher disease , 2020, Journal of cellular and molecular medicine.

[6]  A. Pinna,et al.  Mean Platelet Volume, Red Cell Distribution Width, and Complete Blood Cell Count Indices in Retinal Vein Occlusions , 2020, Ophthalmic epidemiology.

[7]  T. McMahon.  Red Blood Cell Deformability, Vasoactive Mediators, and Adhesion , 2019, Front. Physiol..

[8]  J. Pernow,et al.  Red blood cell dysfunction: a new player in cardiovascular disease. , 2019, Cardiovascular research.

[9]  N. Pfeiffer,et al.  Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study. , 2019, Journal of hypertension.

[10]  I. Rudan,et al.  Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors , 2019, Journal of global health.

[11]  J. Weisel,et al.  Red blood cells: the forgotten player in hemostasis and thrombosis , 2019, Journal of thrombosis and haemostasis : JTH.

[12]  T. Anothaisintawee,et al.  Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis , 2018, Expert review of clinical pharmacology.

[13]  Ying Su,et al.  The Exposure of Phosphatidylserine Influences Procoagulant Activity in Retinal Vein Occlusion by Microparticles, Blood Cells, and Endothelium , 2018, Oxidative medicine and cellular longevity.

[14]  Anna Bogdanova,et al.  Squeezing for Life – Properties of Red Blood Cell Deformability , 2018, Front. Physiol..

[15]  J. Jumper,et al.  Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) , 2018, Clinical ophthalmology.

[16]  M. Kelm,et al.  Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia , 2017, Antioxidants & redox signaling.

[17]  A. Gori,et al.  Erythrocyte oxidative stress is associated with cell deformability in patients with retinal vein occlusion , 2016, Journal of thrombosis and haemostasis : JTH.

[18]  S. E. Bradshaw,et al.  Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion , 2016, BMC Ophthalmology.

[19]  A. Yılmaz,et al.  Altered platelet morphological parameters in patients with retinal vein occlusion. , 2016, European review for medical and pharmacological sciences.

[20]  Christopher J Brady,et al.  Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion. , 2016, Ophthalmology.

[21]  D. Simon,et al.  Atherothrombosis: Seeing Red? , 2015, Circulation.

[22]  J. G. Mohanty,et al.  Red blood cell membrane-facilitated release of nitrite-derived nitric oxide bioactivity. , 2015, Biochemistry.

[23]  P. Campochiaro,et al.  Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. , 2015, Ophthalmology (Rochester, Minn.).

[24]  S. Sivaprasad,et al.  The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary , 2015, Eye.

[25]  Min-Chi Chen,et al.  Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma , 2014, BMC Ophthalmology.

[26]  Y. Colin,et al.  Red cell adhesion in human diseases , 2014, Current opinion in hematology.

[27]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[28]  Sharon D. Solomon,et al.  Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. , 2013, American journal of ophthalmology.

[29]  S. R. Abel,et al.  Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion , 2013, The Annals of pharmacotherapy.

[30]  Dao-Yi Yu,et al.  Alterations to vascular endothelium in the optic nerve head in patients with vascular comorbidities. , 2013, Experimental eye research.

[31]  Yasin Cinar,et al.  The Mean Platelet Volume in Patients with Retinal Vein Occlusion , 2013, Journal of ophthalmology.

[32]  P. Campochiaro,et al.  Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. , 2013, Ophthalmology.

[33]  M. von Lindern,et al.  Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. , 2013, Blood.

[34]  Alison M. Forsyth,et al.  The effects of membrane cholesterol and simvastatin on red blood cell deformability and ATP release. , 2012, Microvascular research.

[35]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[36]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.

[37]  Beppie van den Bogaerde,et al.  Clinical practice , 2011, European Journal of Pediatrics.

[38]  M. Laouri,et al.  The burden of disease of retinal vein occlusion: review of the literature , 2011, Eye.

[39]  Y. Colin,et al.  Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion , 2011, Journal of thrombosis and haemostasis : JTH.

[40]  Gabriel Coscas,et al.  Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[41]  S. Yale,et al.  Virchow’s Contribution to the Understanding of Thrombosis and Cellular Biology , 2010, Clinical Medicine & Research.

[42]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[43]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[44]  T. Wong,et al.  Clinical practice. Retinal-vein occlusion. , 2010, The New England journal of medicine.

[45]  K. Langová,et al.  The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[46]  C. Pournaras,et al.  [Isovolumic hemodilution in the management of the acute phase of central retinal vein occlusion: a pilot study]. , 2009, Journal francais d'ophtalmologie.

[47]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[48]  P. Henson,et al.  Apoptotic Cell Recognition: Will the Real Phosphatidylserine Receptor(s) Please Stand up? , 2008, Current Biology.

[49]  J. Piette,et al.  Endogenous erythroid colony formation in patients with retinal vein occlusion. , 2007, Ophthalmology.

[50]  F. Sofi,et al.  Role of haemorheological factors in patients with retinal vein occlusion , 2007, Thrombosis and Haemostasis.

[51]  A. Mathis,et al.  [Treatment of central retinal vein occlusion by isovolemic hemodilution]. , 2007, Journal francais d'ophtalmologie.

[52]  T. Williamson.  A “throttle” mechanism in the central retinal vein in the region of the lamina cribrosa , 2006, British Journal of Ophthalmology.

[53]  S. Berliner,et al.  Aggregation of red blood cells in patients with Gaucher disease , 2006, British journal of haematology.

[54]  P. Mitchell,et al.  Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. , 2006, Archives of ophthalmology.

[55]  W. Vainchenker,et al.  A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. , 2005, Trends in molecular medicine.

[56]  Michel Paques,et al.  Systolodiastolic variations of blood flow during central retinal vein occlusion: exploration by dynamic angiography , 2005, British Journal of Ophthalmology.

[57]  J. Cruysberg,et al.  Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? , 2005, Thrombosis and Haemostasis.

[58]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[59]  A. Tefferi,et al.  Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia , 2005, British journal of haematology.

[60]  M. Telen.  Erythrocyte adhesion receptors: blood group antigens and related molecules. , 2005, Transfusion medicine reviews.

[61]  Z. Berneman,et al.  Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. , 2004, Platelets.

[62]  D. Mikhailidis,et al.  Mean platelet volume as an indicator of platelet activation: methodological issues , 2003, Platelets.

[63]  S. Hayreh,et al.  Hematologic abnormalities associated with various types of retinal vein occlusion , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[64]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[65]  Stuart H. Orkin,et al.  Diversification of haematopoietic stem cells to specific lineages , 2000, Nature Reviews Genetics.

[66]  C. Greven,et al.  Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance. , 1997, American journal of ophthalmology.

[67]  Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. , 1997, Archives of ophthalmology.

[68]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[69]  T. Williamson,et al.  Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. , 1996, The British journal of ophthalmology.

[70]  M. Reim,et al.  Role of rheologic factors in patients with acute central retinal vein occlusion. , 1996, Ophthalmology.

[71]  M. Reim,et al.  Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. , 1995, German journal of ophthalmology.

[72]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[73]  M. Wiederholt,et al.  Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution. , 1990, The British journal of ophthalmology.

[74]  G. Coscas,et al.  Increased red blood cell aggregation in retinal vein occlusion , 1990, British journal of haematology.

[75]  P. Moyenin.  [Retinal vascular occlusions]. , 1989, La Revue du praticien.

[76]  S S Hayreh,et al.  Classification of central retinal vein occlusion. , 1983, Ophthalmology.

[77]  G. Hutchins,et al.  CENTRAL RETINAL VEIN OCCLUSION: A Prospective Histopathologic Study of 29 Eyes in 28 Cases , 2005, Retina.

[78]  M. Romem,et al.  Photocoagulation in retinal vein occlusion. , 1981, Annals of ophthalmology.